Compass Point analyst Rommel Dionisio upgraded Trulieve Cannabis to Buy from Neutral with a price target of $17, up from $11, citing his view that competition in the company's core Florida market is likely to decelerate in the near-term as he expects Trulieve's less profitable competitors to slow down their pace of opening cultivation facilities and dispensaries. He also points to the growing possibility for Florida voters to pass a referendum in next November's election to legalize the recreational sale of cannabis, naming Trulieve as the "primary beneficiary" if that were to happen.

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on study dosing, a completed acquisition and a research partnership. ATAI ANNOUNCES DOSING... To see the rest of the story go to thefly.com. See Story Here